Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,065,188
  • Shares Outstanding, K 27,617
  • Annual Sales, $ 148,360 K
  • Annual Income, $ -97,170 K
  • 60-Month Beta 1.99
  • Price/Sales 7.24
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 2.13
  • Number of Estimates 5
  • High Estimate 4.36
  • Low Estimate -1.22
  • Prior Year -2.01
  • Growth Rate Est. (year over year) +205.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.21 +2.12%
on 07/31/20
53.73 -29.28%
on 07/09/20
-13.03 (-25.53%)
since 07/07/20
3-Month
37.21 +2.12%
on 07/31/20
53.73 -29.28%
on 07/09/20
-6.12 (-13.87%)
since 05/07/20
52-Week
24.82 +53.10%
on 03/16/20
76.98 -50.64%
on 02/13/20
-0.48 (-1.25%)
since 08/07/19

Most Recent Stories

More News
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020

Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on August 10, 2020. Following the release, company management...

ESPR : 38.00 (-1.48%)
After Yesterday's Decline of 1.20%, Esperion Therape Offers Investors Better Value

Esperion Therape (NASDAQ:ESPR) traded in a range yesterday that spanned from a low of $50.35 to a high of $52.40. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of...

ESPR : 38.00 (-1.48%)
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement

Esperion (NASDAQ: ESPR) announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE). Earlier this month, Esperion completed the transfer to DSE...

ESPR : 38.00 (-1.48%)
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL(TM) (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions

Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American Diabetes Association 80 Scientific Sessions. According to the...

ESPR : 38.00 (-1.48%)
Esperion Confirms NEXLETOL(TM) (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER

Esperion (NASDAQ: ESPR) today confirms it has received notice that the Institute of Clinical and Economic Review (ICER) plans to assess new non-statin medicines for hypercholesterolemia in the U.S., including...

ESPR : 38.00 (-1.48%)
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference

Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Goldman Sachs 41st Annual Global Healthcare...

ESPR : 38.00 (-1.48%)
Why Is Esperion Therapeutics (ESPR) Down 1.5% Since Last Earnings Report?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ESPR : 38.00 (-1.48%)
Esperion Therape Rises 4.41% on Heavy Volume: Watch For Potential Pullback

Esperion Therape (NASDAQ:ESPR) traded in a range yesterday that spanned from a low of $42.05 to a high of $44.84. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high...

ESPR : 38.00 (-1.48%)
All You Need to Know About Esperion Therapeutics (ESPR) Rating Upgrade to Buy

Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ESPR : 38.00 (-1.48%)
Esperion Announces Commercial Availability of NEXLIZET(TM) (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering

- First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering -

ESPR : 38.00 (-1.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ESPR with:

Business Summary

Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.

See More

Key Turning Points

2nd Resistance Point 39.52
1st Resistance Point 38.76
Last Price 38.00
1st Support Level 37.59
2nd Support Level 37.18

See More

52-Week High 76.98
Fibonacci 61.8% 57.05
Fibonacci 50% 50.90
Fibonacci 38.2% 44.75
Last Price 38.00
52-Week Low 24.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar